Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

By sjmartinez • October 15, 2024

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron JJ, Smith DM; ACTIV-2/A5401 Study Team. Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. J Infect Dis. 2024 Oct 14:jiae501. doi: 10.1093/infdis/jiae501. Epub ahead of print. PMID: 39400063.

Tags: covid-19, COVID-19 treatment, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, non-hospitalized adults, Publications, SARS-CoV-2, symptom rebound, viral rebound

Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort

Boriek AM, Gordon J, Gwon Y, Adami A, Porszasz J, Rossiter HB, Rambod M, Chandra D, Diaz AA, Kinney GL, Make BJ, McDonald MN, Regan[...]

Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia

Cai J, Yue C, Tomassetti S. Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid[...]

Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin

Haouzi P, Stringer WW, Mccully J, Pichurko BM. Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin. Eur J[...]